查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018514

基因檢測市場：全球市場按產品類型、技術、檢測類型、應用和最終用戶分類的預測——2026-2032年

Hereditary Testing Market by Product Type, Technology, Testing Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因檢測市場價值將達到 60 億美元，到 2026 年將成長到 64.8 億美元，到 2032 年將達到 106.3 億美元，複合年成長率為 8.49%。

主要市場統計數據
基準年 2025 60億美元
預計年份：2026年 64.8億美元
預測年份 2032 106.3億美元
複合年成長率 (%) 8.49%

對基因檢測進行權威概述，整合臨床需求、技術進步、政策趨勢和相關人員影響，以進行策略規劃。

基因檢測領域獨具特色，臨床需求、技術創新和不斷變化的監管預期在此交匯融合。本書整體情況概述了基因檢測的現狀，重點關注需求促進因素、實現更深入基因洞察的技術途徑以及推動其應用的機構相關人員。此外，本書也闡明了基因檢測為何從一種小眾的臨床輔助手段轉變為精準醫療工作流程的核心要素，包括診斷確認、生育計畫和治療指南。

確定關鍵的技術、監管和臨床轉折點，這些轉折點將重塑基因檢測在醫療保健服務中的引入、檢驗和整合。

目前基因檢測正經歷一場由技術、臨床和政策領域各方力量共同推動的變革。定序處理能力、分析演算法和檢查室自動化的進步，促進了從標靶單基因檢測方法向綜合多基因和全外EXOME策略的轉變（尤其是在臨床相關的情況下）。同時，樣本製備和試劑設計的改進縮短了檢測時間，並提高了突變檢測靈敏度，使得將基因檢測結果常規納入臨床決策成為可能。

對 2025 年美國關稅對基因檢測臨床服務供應鏈、採購和連續性的營運和策略影響進行全面分析。

2025年美國關稅格局對基因檢測服務提供者、醫療設備製造商和檢查室網路提出了多層次的營運和策略考量。關稅帶來的成本壓力影響了進口設備和特殊試劑，迫使採購團隊重新評估供應商合約和庫存策略。同時，檢查室和試劑供應商開始多元化採購管道並整合供應商，以減少供應鏈中斷，並維持臨床合作夥伴的檢測連續性。

詳細的細分分析揭示了設備、試劑、技術、測試方法、臨床應用和最終用戶如何定義差異化的採用管道和價值提案。

從精細的市場細分觀點來看，臨床效用、技術能力和商業性機會如何在產品類型、技術、檢測類型、應用和最終用戶等維度上相互交織。按產品類型分類，市場包括驅動分析能力的儀器、支援檢測工作流程的試劑和試劑盒，以及包括定序分析、結果解讀和報告在內的服務。儀器決定了性能極限和處理能力預期；試劑和試劑盒決定了每次檢測的可靠性和成本結構；而服務則將技術輸出轉化為臨床適用的資訊。

區域比較分析突顯了美洲、歐洲、中東和非洲以及亞太地區在基因檢測的監管、報銷、基礎設施和採用率方面的差異。

區域趨勢是基因檢測商業化策略、監管重點和臨床應用模式的關鍵促進因素。在美洲，整合的醫療保健系統、支付方對診斷價值日益增強的認知，以及能夠快速擴展分子檢測服務的蓬勃發展的私人實驗室產業，正在推動基因檢測的臨床應用。這種環境有利於先進定序技術和綜合分析服務的早期應用，同時也帶來了在結果報告時間和成本效益方面的競爭壓力。

策略競爭資訊解釋了產品廣度、試劑供應穩定性、分析專業知識和夥伴關係如何決定基因檢測領域的領導地位。

基因檢測領域的競爭動態由成熟的診斷實驗室、專業試劑生產商、儀器供應商和新興的解讀服務供應商共同塑造。一些機構透過平台廣度脫穎而出，提供儀器和整合試劑生態系統，簡化檢測流程並減輕檢驗負擔。另一些機構則在解讀深度上競爭，投資於精心整理的變異資料庫、臨床決策支援工具和經臨床檢驗的報告框架，以加速臨床醫師對這些工具的採納。

為領導者提供切實可行的、有影響力的建議，以加強整個市場基因檢測的營運韌性，增強臨床信心，並加速負責任的部署。

產業領導者應推動一系列合作舉措，將洞察轉化為營運優勢，並加速負責任的臨床部署。首先，應優先考慮檢測方法的互通性和多廠商檢驗，以降低供應鏈風險，並在必要時實現快速技術過渡。這將最大限度地減少營運中斷，並確保檢查室能夠為臨床醫生和患者提供持續的醫療服務。其次，應投資於變異解讀基礎設施和認證報告標準，以縮短臨床醫生的決策週期，並提高對檢測結果的信心。

研究結果透過透明且可重複的調查方法檢驗，該方法結合了相關人員訪談、監管和臨床證據審查、跨領域映射和情境分析。

本分析的調查方法融合了定性和定量方法，以確保獲得可靠且可操作的見解。主要工作包括與臨床實驗室管理人員、採購負責人、臨床遺傳學家和監管顧問進行結構化訪談，以了解實際操作情況、證據重點以及推廣應用的障礙。除這些訪談外，還對監管指南、同行評審的臨床研究和變異解讀標準進行了系統性回顧，從而為基於當前臨床和政策背景的策略建議提供了支持。

簡潔扼要的策略結論強調了將技術創新、營運韌性、證據生成和以臨床醫生為中心的服務相結合的必要性。

這個結論將分析結果整合為一個清晰的策略挑戰：隨著基因檢測作為臨床領域的不斷成熟，機會將屬於那些能夠平衡技術卓越性、營運韌性和以臨床醫生為中心的解讀能力的機構。技術進步將持續拓展診斷能力，但其應用速度將取決於臨床效用的證據、與保險報銷的兼容性以及檢查室和醫療保健系統的營運準備。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 基因檢測市場：依產品類型分類

  • 裝置
  • 試劑和試劑盒
  • 服務

第9章 基因檢測市場：依技術分類

  • 微陣列
    • 比較基因雜合反應
    • 基因表現
    • SNP基因基因型鑒定
  • NGS
    • EXOME定序
    • 目標序列
    • 全基因組定序
  • PCR
    • 數位PCR
    • qPCR
    • RT-PCR

第10章：依檢測類型分類的基因檢測市場

  • 基因帶原檢測
  • 新生兒篩檢
  • 藥物基因體學
  • 預測性測試
  • 產前檢查

第11章 基因檢測市場：依應用領域分類

  • 心血管疾病
  • 腫瘤學
  • 罕見疾病
  • 生殖醫學

第12章 基因檢測市場：依最終用戶分類

  • 診斷檢測實驗室
  • 醫院和診所
  • 研究機構

第13章 基因檢測市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 基因檢測市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 基因檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國基因檢測市場

第17章：中國基因檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 23andMe, Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Color Genomics, Inc.
  • CooperSurgical, Inc.
  • Devyser AB
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • Hologic, Inc.
  • Igenomix SL
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Mapmygenome India Ltd.
  • MedGenome, Inc.
  • MyHeritage Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • PerkinElmer, Inc.
  • Qiagen NV
  • Quest Diagnostics, Inc.
  • SOPHiA GENETICS SA
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-A339DAEFA85A

The Hereditary Testing Market was valued at USD 6.00 billion in 2025 and is projected to grow to USD 6.48 billion in 2026, with a CAGR of 8.49%, reaching USD 10.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.00 billion
Estimated Year [2026] USD 6.48 billion
Forecast Year [2032] USD 10.63 billion
CAGR (%) 8.49%

An authoritative introduction to hereditary testing that synthesizes clinical demand, technological progress, policy dynamics, and stakeholder implications for strategic planning

Hereditary testing occupies a unique intersection of clinical need, technological innovation, and shifting regulatory expectations. This introduction frames the landscape by highlighting the drivers that shape demand, the technological vectors enabling deeper genetic insight, and the institutional stakeholders responsible for adoption. It clarifies why hereditary testing has moved from a niche clinical adjunct to a core element of precision medicine workflows, including diagnostic confirmation, reproductive planning, and therapeutic guidance.

The narrative begins with clinical demand: growing clinician familiarity with genetic contributors to disease, the expansion of indications for genetic screening, and the integration of genetic risk into care pathways. It then moves to technology, underscoring how incremental improvements in instrumentation, reagent chemistry, and analytic software have increased throughput, confidence, and clinical utility. Regulatory evolution and payer recognition are introduced as amplifiers of clinical adoption, while persistent operational frictions-data interoperability, variant interpretation burden, and sample logistics-are defined as areas requiring strategic focus.

Finally, the introduction establishes the report's purpose: to synthesize multi-dimensional trends into actionable insight for executives, clinical leaders, and product teams. It sets reader expectations for subsequent sections that dissect transformative shifts, tariff impacts, segmentation dynamics, regional differentials, competitive positioning, and practical recommendations aimed at accelerating responsible adoption and sustainable commercial growth.

Identifying the decisive technological, regulatory, and clinical inflection points reshaping how hereditary testing is adopted, validated, and integrated into healthcare delivery

The hereditary testing landscape is in a state of purposeful transformation driven by converging technological, clinical, and policy forces. Advances in sequencing throughput, analytic algorithms, and laboratory automation have catalyzed a shift from targeted single-gene approaches to comprehensive multi-gene and whole-exome strategies where clinically relevant. Simultaneously, improvements in sample preparation and reagent design have reduced turnaround time and improved variant detection sensitivity, enabling more routine integration of genetic results into clinical decision-making.

Clinicians and health systems are responding to evidence that genetic insights can change care pathways, which is prompting expanded indications for carrier testing, newborn screening, and pharmacogenomic profiling. Payors and health technology assessors are increasingly recognizing the value of diagnostics that enable earlier intervention, though reimbursement policies remain heterogeneous across jurisdictions. Regulatory frameworks are also evolving; regulators emphasize analytical validity, clinical utility, and responsible reporting, which raises the bar for laboratories and vendors while instilling greater confidence among clinicians and patients.

Concurrently, data governance and interoperability concerns are shaping the commercial environment. The need to harmonize variant interpretation and to share de-identified datasets for clinical annotation is becoming an operational imperative. In short, the sector's transformation is not only technological but institutional: stakeholders across clinical, laboratory, regulatory, and payer domains are adjusting incentives and practices to embed hereditary testing more systematically into care delivery.

Comprehensive analysis of the operational and strategic consequences of 2025 United States tariffs on hereditary testing supply chains, procurement, and clinical service continuity

The 2025 tariff landscape in the United States introduced layered operational and strategic considerations for hereditary testing providers, device manufacturers, and laboratory networks. Tariff-driven cost pressures affected imported instrumentation and specialized reagents, prompting procurement teams to re-evaluate supplier contracts and inventory strategies. At the same time, laboratories and reagent suppliers initiated sourcing diversification strategies and supplier consolidation to buffer supply chain shocks and to preserve test continuity for clinical partners.

These trade measures also influenced the pace at which laboratories invested in capital-intensive upgrades. Decision-makers weighed the near-term cost increases against long-term clinical benefits and operational efficiencies of adopting newer platforms. Procurement cycles extended as organizations sought to renegotiate terms, identify domestic suppliers where feasible, and validate alternative reagents and consumables to maintain assay performance and compliance.

Beyond procurement, the tariff environment highlighted the importance of operational resilience. Stakeholders accelerated validation of contingency workflows, expanded multi-vendor compatibility in assay design, and increased emphasis on assay robustness to minor reagent or instrument changes. In parallel, commercial teams revisited pricing strategies, contractual risk-sharing mechanisms, and service-level commitments to remain competitive while protecting margins. Ultimately, the tariff context underscored the value of flexible supply chains, proactive supplier partnerships, and scenario-based planning for maintaining uninterrupted clinical services.

In-depth segmentation analysis revealing how instruments, reagents, technologies, testing modalities, clinical applications, and end users define differentiated adoption pathways and value propositions

A nuanced segmentation lens reveals where clinical utility, technological capability, and commercial opportunity intersect across product, technology, testing type, application, and end-user dimensions. By product type, the landscape comprises instruments driving analytical capacity, reagents and kits enabling assay workflows, and services that include sequencing runs, interpretation, and reporting. Instruments set the performance envelope and throughput expectations, reagents and kits dictate per-test reliability and cost profile, and services translate technical output into clinically actionable information.

Across technology, the market divides into microarray, next-generation sequencing, and PCR modalities. Microarray implementations include comparative genomic hybridization, gene expression arrays, and SNP genotyping approaches that are especially relevant for copy number and common variant assessments. Next-generation sequencing spans exome sequencing, targeted sequencing panels, and whole genome sequencing, each balancing breadth of coverage with data complexity and interpretation requirements. PCR technologies encompass digital PCR, qPCR, and RT-PCR, providing high-sensitivity, targeted options for variant confirmation and specific diagnostic use cases.

Testing type segmentation shows distinct clinical pathways: carrier testing supports reproductive decision-making; newborn screening identifies early disease to enable prompt intervention; pharmacogenomics guides medication selection and dosing; predictive testing evaluates future disease risk; and prenatal testing informs fetal genetic assessment. Application segmentation highlights cardiovascular disease, oncology, rare diseases, and reproductive health as areas where hereditary testing offers high clinical leverage, though the clinical workflows and evidence requirements differ by application. End-user segmentation clarifies adoption channels: diagnostic laboratories operationalize assays at scale, hospitals and clinics integrate testing into patient pathways, and research institutes drive methodology refinement and variant interpretation. Taken together, these intersecting segments create distinct value chains and adoption barriers that require tailored commercial and clinical strategies.

Comparative regional insights highlighting how the Americas, Europe Middle East & Africa, and Asia-Pacific differ in regulation, reimbursement, infrastructure, and adoption velocity for hereditary testing

Regional dynamics are a primary determinant of commercialization strategy, regulatory priorities, and clinical adoption patterns in hereditary testing. In the Americas, clinical adoption benefits from integrated health systems, growing payer recognition of diagnostic value, and an active private laboratory sector able to scale molecular services rapidly. This environment fosters early adoption of advanced sequencing approaches and comprehensive interpretation services, but also creates competitive pressure around turnaround times and cost-efficiency.

Europe, the Middle East & Africa presents a heterogeneous environment in which regulatory rigor, reimbursement frameworks, and healthcare infrastructure vary widely. Several markets in this region prioritize standardized variant interpretation and cross-border data sharing initiatives, while others focus on expanding basic access to newborn and carrier screening. Vendors and laboratories operating here must navigate diverse regulatory regimes and adapt offerings to local clinical priorities and procurement mechanisms.

The Asia-Pacific region combines high-volume public health initiatives with rapidly advancing private sector capabilities. Large-scale population health programs and expanding genomic research initiatives drive demand for scalable sequencing platforms and cost-effective reagents. At the same time, adoption is tempered by variable regulatory processes, localized reimbursement policies, and the need for training in variant curation and clinical integration. Across regions, strategic market entry requires calibrating product offerings, service models, and partnership approaches to align with differing healthcare delivery models and stakeholder expectations.

Strategic competitive intelligence that explains how product breadth, reagent resilience, interpretation expertise, and partnerships determine leadership in hereditary testing

Competitive dynamics in hereditary testing are shaped by a mix of established diagnostic laboratories, specialized reagent manufacturers, instrument vendors, and emerging interpretation service providers. Some organizations differentiate through platform breadth, offering instruments and integrated reagent ecosystems that simplify laboratory workflows and reduce validation burden. Others compete on interpretation depth, investing in curated variant databases, clinical decision support tools, and clinically validated reporting frameworks to speed clinician uptake.

Partnerships between instrument manufacturers and laboratory networks have become strategic levers for expanding service footprints and ensuring consumables continuity. Similarly, reagent innovators that prioritize assay robustness and multi-vendor compatibility gain appeal among laboratories seeking resilience against supply shocks. Interpretation service providers that embed standardized variant classification processes and transparent report semantics help clinicians act decisively on genetic findings, strengthening clinical trust and downstream test utilization.

Across competitive plays, differentiation often rests on the ability to demonstrate clinical validity and utility through peer-reviewed evidence, to support seamless integration with laboratory information systems and electronic health records, and to offer scalable service models that address variable throughput needs. Intellectual property in assay chemistry and proprietary bioinformatics can confer advantage, but sustainable leadership also requires robust customer support, regulatory agility, and demonstrated success in real-world clinical deployments.

Practical, high-impact recommendations for leaders to strengthen operational resilience, enhance clinical trust, and accelerate responsible adoption of hereditary testing across markets

Industry leaders should pursue a coordinated set of actions to convert insight into operational advantage and to accelerate responsible clinical adoption. First, prioritize assay interoperability and multi-vendor validation to reduce supply chain risk and to facilitate rapid technology swaps when required. This reduces operational disruptions and enables laboratories to maintain continuity of care for clinicians and patients. Next, invest in variant interpretation infrastructure and certified reporting standards to shorten clinician decision cycles and to increase confidence in test results.

Additionally, develop flexible commercial models that align pricing and service levels with clinical outcomes and throughput variability. Contract innovations can include risk-sharing clauses tied to turnaround time guarantees or bundled interpretation services that streamline clinician uptake. Strengthening regional partnerships is also critical: align local regulatory and reimbursement strategies with partner capabilities to facilitate market entry and to accelerate adoption. From a product perspective, continue to optimize reagent formulations for robustness across ambient conditions and instrument platforms, while improving assay automation to lower hands-on time and error rates.

Finally, embed scenario-based supply chain planning and cross-functional simulation exercises into annual strategic reviews. These practices will improve responsiveness to trade policy shifts, raw material constraints, and demand surges. Collectively, these steps will position organizations to meet clinician needs, improve patient outcomes, and sustain commercial momentum in a complex and evolving landscape.

Transparent, reproducible research methodology combining stakeholder interviews, regulatory and clinical evidence review, cross-segmentation mapping, and scenario analysis to validate findings

The research methodology underpinning this analysis integrates qualitative and quantitative approaches to ensure robust, actionable insight. Primary engagement involved structured interviews with clinical laboratory directors, procurement officers, clinical geneticists, and regulatory advisers to capture operational realities, evidence priorities, and adoption barriers. These conversations were supplemented by a systematic review of regulatory guidance, peer-reviewed clinical studies, and standards for variant interpretation to ground strategic recommendations in current clinical and policy contexts.

Analytical steps included cross-segmentation mapping to identify where technology, test type, application, and end-user characteristics converge to create unique adoption pathways. Scenario analysis examined the operational implications of supply chain disruptions, pricing pressures, and regulatory shifts in order to propose resilient commercial and operational responses. Data validation was achieved through triangulation across interview insights, regulatory documentation, and published clinical utility studies, ensuring the narrative reflects both practitioner experience and the scientific literature.

Throughout the methodology, emphasis was placed on reproducibility and transparency: assumptions for scenario exercises are documented, interview protocols followed standardized guides, and interpretation frameworks referenced established classification systems. This approach ensures that recommendations are traceable to evidence and that strategic options can be customized to organizational contexts with confidence.

Concise strategic conclusion emphasizing the need to pair technological innovation with operational resilience, evidence generation, and clinician-centered services to realize long-term value

The conclusion synthesizes the analysis into a clear strategic imperative: hereditary testing will continue to mature as a clinical discipline, but opportunities will accrue to organizations that align technical excellence with operational resilience and clinician-focused interpretation. Technological advances will keep expanding diagnostic capability, yet the pace of adoption will depend on evidence of clinical utility, reimbursement alignment, and operational readiness within laboratories and healthcare systems.

To capture value responsibly, organizations must balance investment in cutting-edge platforms with investments in interpretation infrastructure and supply chain diversification. Regulatory compliance and transparent reporting frameworks will be central to earning clinician trust and payer recognition. Additionally, regional strategy must reflect local regulatory nuance and healthcare delivery models while leveraging global partnerships for innovation and scale.

In sum, the path forward requires integrated strategies that marry product innovation with pragmatic operational planning and clinician-centered service models. Executives should prioritize initiatives that reduce friction in test delivery, strengthen evidence generation, and build resilient supplier relationships to ensure hereditary testing delivers sustainable clinical benefit and organizational return.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hereditary Testing Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Services

9. Hereditary Testing Market, by Technology

  • 9.1. Microarray
    • 9.1.1. Comparative Genomic Hybridization
    • 9.1.2. Gene Expression
    • 9.1.3. SnP Genotyping
  • 9.2. NGS
    • 9.2.1. Exome Sequencing
    • 9.2.2. Targeted Sequencing
    • 9.2.3. Whole Genome Sequencing
  • 9.3. PCR
    • 9.3.1. Digital PCR
    • 9.3.2. qPCR
    • 9.3.3. RT-PCR

10. Hereditary Testing Market, by Testing Type

  • 10.1. Carrier Testing
  • 10.2. Newborn Screening
  • 10.3. Pharmacogenomics
  • 10.4. Predictive Testing
  • 10.5. Prenatal Testing

11. Hereditary Testing Market, by Application

  • 11.1. Cardiovascular Disease
  • 11.2. Oncology
  • 11.3. Rare Diseases
  • 11.4. Reproductive Health

12. Hereditary Testing Market, by End User

  • 12.1. Diagnostic Laboratories
  • 12.2. Hospitals & Clinics
  • 12.3. Research Institutes

13. Hereditary Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hereditary Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hereditary Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Hereditary Testing Market

17. China Hereditary Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 23andMe, Inc.
  • 18.6. Abbott Laboratories
  • 18.7. Agilent Technologies, Inc.
  • 18.8. BGI Group
  • 18.9. Bio-Rad Laboratories, Inc.
  • 18.10. Bio-Techne Corporation
  • 18.11. Color Genomics, Inc.
  • 18.12. CooperSurgical, Inc.
  • 18.13. Devyser AB
  • 18.14. Eurofins Scientific SE
  • 18.15. Exact Sciences Corporation
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. Fulgent Genetics, Inc.
  • 18.18. Hologic, Inc.
  • 18.19. Igenomix S.L.
  • 18.20. Illumina, Inc.
  • 18.21. Invitae Corporation
  • 18.22. Laboratory Corporation of America Holdings
  • 18.23. Mapmygenome India Ltd.
  • 18.24. MedGenome, Inc.
  • 18.25. MyHeritage Ltd.
  • 18.26. Myriad Genetics, Inc.
  • 18.27. Natera, Inc.
  • 18.28. NeoGenomics Laboratories, Inc.
  • 18.29. PerkinElmer, Inc.
  • 18.30. Qiagen N.V.
  • 18.31. Quest Diagnostics, Inc.
  • 18.32. SOPHiA GENETICS S.A.
  • 18.33. Takara Bio Inc.
  • 18.34. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEREDITARY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HEREDITARY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HEREDITARY TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEREDITARY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEREDITARY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEREDITARY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEREDITARY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENE EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENE EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENE EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SNP GENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SNP GENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEREDITARY TESTING MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEREDITARY TESTING MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEREDITARY TESTING MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEREDITARY TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEREDITARY TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEREDITARY TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEREDITARY TESTING MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEREDITARY TESTING MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEREDITARY TESTING MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RT-PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RT-PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RT-PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARRIER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARRIER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARRIER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEREDITARY TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEREDITARY TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEREDITARY TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS HEREDITARY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GCC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 180. GCC HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. G7 HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 207. G7 HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. G7 HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. NATO HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 214. NATO HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 216. NATO HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. NATO HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES HEREDITARY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA HEREDITARY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA HEREDITARY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA HEREDITARY TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA HEREDITARY TESTING MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA HEREDITARY TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA HEREDITARY TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA HEREDITARY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)